-
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
•
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical study of its ASC47 in Australia. This adipose-targeted drug candidate, developed in-house, is designed to achieve weight loss without losing muscle mass. Clinical Study ResultsIn the study, ASC47 demonstrated a half-life of up to 26…
-
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
•
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for a new indication for its PD-L1 inhibitor Imfinzi (durvalumab). The approval allows Imfinzi to be used in combination with chemotherapy for adults with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC), specifically for patients without…
-
Huihe Healthcare’s K-Clip Wins Chinese Approval for Tricuspid Regurgitation Treatment
•
Shanghai-based Huihe Healthcare, a developer of structural heart disease intervention medical devices, announced receiving marketing approval in China for its K-Clip transcatheter tricuspid valve repair system. This approval marks a significant milestone in the treatment of tricuspid regurgitation. Innovation and Market ImpactK-Clip is the first of its kind in China…
-
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
•
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy Officer. Based in the United States, Michael will report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. This strategic move aims to enhance Harbour BioMed’s global influence and business expansion. Role…
-
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
•
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization of HexaBody-CD38 (GEN3014). Consequently, clinical development of the drug will be terminated. The decision was based on…
-
Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the National Medical Products Administration (NMPA) for its sacituzumab tirumotecan (SKB264/MK-2870). The approval allows the use of this TROP2-targeted antibody drug conjugate (ADC) in adult patients with EGFR mutation-positive locally advanced or metastatic non-squamous non-small cell…
-
Illumina Responds to Chinese MOFCOM Notice Amid Sequencing Instrument Export Ban
•
US major Illumina (NASDAQ: ILMN), which was included in a list of unreliable entities issued by China’s Ministry of Commerce (MOFCOM) earlier this year, has responded to the notice from MOFCOM on March 4, 2025. The company faces a prohibition on exporting sequencing instruments into China and has stated its…
-
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to regular approval for Elahere (mirvetuximab soravtansine) has been accepted by the National Medical Products Administration (NMPA). This antibody drug conjugate (ADC) targets folate receptor α (FRα) and represents a significant step forward in the treatment…
